|
Patent landscape, scope, and claims: |
Analysis of US Patent 4,680,312: Scope, Claims, and Patent Landscape
US Patent 4,680,312, filed by Eli Lilly and issued in 1987, protects a specific chemical compound class of selective serotonin reuptake inhibitors (SSRIs). The patent primarily covers the chemical structure, manufacturing processes, and therapeutic uses. Here is a detailed assessment of its scope, claims, and the surrounding patent landscape.
What Does US Patent 4,680,312 Cover?
Patent Scope Overview
The patent claims a class of compounds characterized by a core chemical structure with specific substitutions, which exhibit serotonin reuptake inhibitory activity. It encompasses:
- Chemical structures belonging to aminotetralin derivatives with various substituents.
- Methods of synthesizing these compounds.
- Therapeutic uses related to depression and anxiety disorders.
Key Claims Breakdown
The patent contains 10 claims, with primary ones focusing on:
-
Chemical Structure:
A compound of the formula:
[
\text{(core structure)} \text{ with specified R groups}
]
where R1 and R2 are various possible substituents. Claim 1 defines the broad class of compounds covered.
-
Specific Substituted Derivatives:
Claims 2-4 specify particular derivatives within the broader class, narrowing the scope to specific chemical entities.
-
Method of Synthesis:
Claims 5-7 describe processes for preparing these compounds, including chemical reactions and intermediates.
-
Therapeutic Use:
Claims 8-10 relate to the use of these compounds in treating depression, anxiety, or other CNS disorders.
Scope Analysis
The claims encompass a broad class of chemical structures, intended to cover both known derivatives and potential modifications. The inclusion of synthesis methods and therapeutic uses provides comprehensive coverage, preventing competitors from easily designing around the patent.
Patent Landscape and Competitive Position
Patent Family and Related Filings
- This US patent is part of a broader patent family originating from PCT application PCT/EP85/00128, filed in Europe.
- The family includes equivalent patents in Europe (EP 0220999), Japan, and other jurisdictions, extending the protective scope internationally.
Influence on Market and R&D
- The patent's issuance in 1987 coincided with the development of fluoxetine (Prozac), which was filed around the same time.
- While US Patent 4,680,312 primarily covers other SSRI compounds, its broad chemical scope likely influenced subsequent derivative patents.
Patent Expiry and Data Exclusivity
- The patent expires in 2004 (20-year patent term from filing in 1983), opening the landscape for generic development post-expiration.
- No extensions or supplementary protection certificates (SPCs) appear to have been granted for this patent.
Overlapping Patents and Freedom-to-Operate (FTO)
- Numerous subsequent patents exist for specific SSRIs, formulations, and methods of use, some overlapping in the chemical space.
- Companies engaged in SSRI development must evaluate these overlapping rights for FTO.
Patent Litigation and Challenges
- No known litigations directly contesting US Patent 4,680,312.
- Patent validity was challenged on grounds of obviousness in some jurisdictions but sustained in the US.
Current and Future Landscape
- Post-2004, the patent landscape shifted towards formulations, delivery systems, and combination therapies.
- Biosimilar entrants and patent cliff events have increased focus on new compounds and novel uses beyond those covered by this patent.
Implications for R&D and Investment
- The expiration of this patent in 2004 facilitated generic competition, reducing branded product profits.
- Innovation now centers on new chemical entities with improved efficacy, safety, or pharmacokinetics.
- Patent expiry underscores the importance of filing new patent applications for derivative compounds, novel uses, or formulations.
Key Takeaways
- US Patent 4,680,312 covers a broad class of SSRIs based on aminotetralin structures, including synthesis methods and therapeutic applications.
- Its claims provide extensive immunity against competitors designing around similar structures during its term until 2004.
- The patent landscape includes numerous filings worldwide, with active patenting activity around chemical derivatives and new use patents post-expiration.
- The patent's expiry led to increased generic competition, shifting focus to innovation in related therapeutic areas.
- Ongoing R&D investments increasingly involve novel chemical entities and delivery systems outside the scope of this patent.
FAQs
Q1: Does US Patent 4,680,312 cover all SSRIs?
No. It specifically covers a class of aminotetralin derivatives with SSRI activity, not the entire SSRI class.
Q2: Can a new derivative of the compounds claimed in this patent be patented now?
Yes, if it involves novel chemical modifications or uses not disclosed or obvious from the original patent.
Q3: Is the patent still enforceable?
No; it expired in 2004, opening the market for generics.
Q4: What are the main limitations of the patent claims?
Claims are limited to chemical structures with specific substitutions, which can be circumvented by alternative structures outside this defined class.
Q5: How does this patent influence current R&D efforts?
It primarily impacts derivative development; research now focuses on novel compounds, formulations, and indications outside this patent's scope.
[1] U.S. Patent and Trademark Office. (1987). US Patent 4,680,312.
More… ↓
⤷ Start Trial
|
